Facial Affect Recognition and Executive Function Abnormalities in ADHD Subjects: An ERP Study
Clinical EEG and Neuroscience · 2025-07 · 56 (4) · 327-341
DOI: 10.1177/15500594241304492 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical EEG and Neuroscience, online erschienen am 19.12.2024. Verfasst von Saghar Vosough und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division Neuropsychology, Department of Psychology, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Executive Function, Evoked Potentials, Facial Expression. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Uniscientia Foundation, the Brain and Trauma Foundation Grison/Switzerland.
Abstract (Originalsprache)
Attention-deficit/hyperactivity disorder (ADHD) affects approximately 12% of children worldwide. With a 50% chance of persistence into adulthood and associations with impairments in various domains, including social and emotional ones, early diagnosis is crucial. The exact neural substrates of ADHD are still unclear. This study aimed to reassess the behavioral and neural metrics of executive functions and neural substrates of facial affect recognition. A total of 117 ADHD patients and 183 healthy controls were evaluated by two Go/NoGo tasks: the classic visual continuous performance test and the emotional continuous performance test, which requires facial affect encoding. Group differences between ADHD subjects and healthy controls were assessed using analysis of covariance (ANCOVA), with age and sex included as covariates. Dependent variables comprised behavioral (number of omission and commission errors, reaction time, and reaction time variability) and neurophysiological measures (event-related potentials [ERPs]). As the main result, we identified significant differences between ADHD patients and healthy controls in all behavioral metrics, one neural marker of action inhibition (P3d) and the facial processing marker (N170). The differences were moderate-to-large when expressed as effect size measures in behavioral variables and small-to-moderate for neurophysiological variables. The small-to-moderate effect sizes obtained from the neurophysiological measures suggest that ERPs are insufficient as sole markers for effectively screening emotion and face processing abnormalities in ADHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division Neuropsychology, Department of Psychology, University of Zurich, Zurich, Switzerland.
- Brain and trauma foundation Grisons/Switzerland, Chur, Switzerland.
- Praxisgemeinschaft für Psychiatrie und Psychotherapie, Lucerne, Switzerland.
- Psychiatrie und Psychotherapie Rapperswil, Rapperswil, Switzerland.
- Department of Psychiatry, Psychotherapy, and Psychosomatics, University of Zurich, Zurich, Switzerland.
ORCID-Profile: Saghar Vosough
Förderung
- the Uniscientia Foundation
- the Brain and Trauma Foundation Grison/Switzerland
Zitieren
APA
Vosough, S., Candrian, G., Kasper, J., Abdel Rehim, H., Eich, D., Müller, A., & Jäncke, L. (2025). Facial Affect Recognition and Executive Function Abnormalities in ADHD Subjects: An ERP Study. Clinical EEG and Neuroscience, 56(4), 327-341. https://doi.org/10.1177/15500594241304492
Vancouver
Vosough S, Candrian G, Kasper J, Abdel Rehim H, Eich D, Müller A, et al. Facial Affect Recognition and Executive Function Abnormalities in ADHD Subjects: An ERP Study. Clinical EEG and Neuroscience. 2025;56(4):327-341. doi:10.1177/15500594241304492
BibTeX
@article{Vosough2025,
author = {Vosough, Saghar and Candrian, Gian and Kasper, Johannes and Abdel Rehim, Hossam and Eich, Dominique and Müller, Andreas and Jäncke, Lutz},
title = {Facial Affect Recognition and Executive Function Abnormalities in ADHD Subjects: An ERP Study},
journal = {Clinical EEG and Neuroscience},
year = {2025},
volume = {56},
number = {4},
pages = {327--341},
doi = {10.1177/15500594241304492}
}
EUVIMED